Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Ms. Michele M. Allegretto

Senior Vice President of Human Resources

Mr. Christopher William Lewis

Vice President of Investor Relations & Corporate Affairs

Mr. Chris M. Calcaterra

Executive Vice President of Global Commercial Operations

Dr. Tomas  Navratil Ph.D.

Chief Development Officer

Dr. Mory  Gharib Ph.D.

Co-Founder

Mr. Joseph E. Gilliam

President & Chief Operating Officer

Ms. Diana A. Scherer

Vice President of Compliance & Deputy General Counsel

Ms. Jane E. Rady

Senior Vice President of Corporate Strategy & Business Development

Mr. Thomas William Burns

Chairman & Chief Executive Officer

Mr. Alex R. Thurman

Senior Vice President & Chief Financial Officer

会社名	時価総額
Edwards Lifesciences Corporation	0M
SofWave Medical Ltd.	0M
Eiken Chemical Co., Ltd.	0M
Nanjing Vishee Medical Technology Co., Ltd	0M
QHSLab, Inc.	0M
Vitrolife AB (publ)	0M
ReWalk Robotics Ltd.	0M
Bone Biologics Corporation	0M
Sinocare Inc.	0M
Hyperfine, Inc.	0M
Viemed Healthcare, Inc.	0M

Glaukos Corporation

Glaukos Corporation 競合他社リスト

主な競合企業